Home » Interviews » Avacta Group transfer technology to BBI Solutions for manufacture of COVID-19 test (Interview)
BBI Solutions Avacta

Avacta Group transfer technology to BBI Solutions for manufacture of COVID-19 test (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the appointment of BBI Solutions as manufacturing partner for the COVID-19 test. Alastair talk us through the details, how the prototype is working and the next steps in bringing it to market. Also discussed is the existing agreement with Daewoong Pharmaceutical which has been expanded to include the SARS-CoV-2 neutralising Affimer reagents and the development of the high throughput COVID-19 test with Adeptrix.

Avacta Group also announced that it has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva.

Join us on our new LinkedIn page

Follow us on LinkedIn